SIMULATIONS PLUS (WKN: 924294) SLP


Seite 1 von 1
Neuester Beitrag: 25.04.21 10:02
Eröffnet am: 18.05.16 19:01 von: Tamakoschy Anzahl Beiträge: 25
Neuester Beitrag: 25.04.21 10:02 von: Michelleiumd. Leser gesamt: 6.603
Forum: Börse   Leser heute: 4
Bewertet mit:
1


 

2458 Postings, 4149 Tage TamakoschySIMULATIONS PLUS (WKN: 924294) SLP

 
  
    #1
1
18.05.16 19:01
Simulations Plus, Inc. is the leading developer of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) and Physiologically-Based Pharmacokinetic (PBPK) modeling and simulation software for the pharmaceutical and biotechnology, industrial chemical, cosmetic, herbicide, and food ingredient industries today. Our software allows pharmaceutical scientists to predict certain key potential endpoints and dynamics, in silico, thereby reducing research & development costs and helping clients make better projects decisions... sooner.

Founded in 1996, Simulations Plus employs over 30 employees (22 with Ph.D. or M.S. degrees) and is publicly-traded on the NASDAQ stock exchange (ticker symbol = SLP).  Our headquarters are based in Lancaster, California, with trusted distributors handling sales and scientific support in Asian territories. All of the top 20 pharmaceutical companies, plus numerous mid- and small-sized companies and all major regulatory agencies, license our software.

Consulting services:   our team of highly-skilled scientists is available to assist with your discovery and development activities on a project-by-project basis. With the acquisition of Cognigen Corporation in 2014, we are now able to offer expanded pharmacodynamic modeling services, NONMEM analysis, and regulatory report writing assistance. The ultimate goal of the merger is to develop tools and systems which bridge PBPK modeling with clinical trial data analysis.

Our expertise, combined with our best-in-class software, provides you with modeling and simulation analyses, from discovery through late-stage clinical development, which can greatly improve your decision-making process.

Training workshops & User Groups:  we offer hands-on introductory and advanced training workshops to learn our software throughout the year. Workshops are held in the United States, Europe, and Asia. We also host an annual Software User Forum each year convened to enhance product knowledge and strengthen communications between Simulations Plus and its worldwide community of users. Additionally, in 2013 scientists from 17 companies formed the GastroPlus™ User Group, which has an online community of 460 members that discuss best practices, provide feedback on new features, and promote the use of PBPK modeling & simulation across various industries.
- See more at: http://www.simulations-plus.com/Aboutus.aspx#sthash.cx9f8iSs.dpuf
.

http://www.simulations-plus.com/PressRelease.aspx

Fundamental:
.
http://de.4-traders.com/SIMULATIONS-PLUS-INC-771786/fundamentals/
.
http://financials.morningstar.com/...ment/is.html?t=SLP&ops=clear
.
http://seekingalpha.com/symbol/SLP  

2458 Postings, 4149 Tage TamakoschyQ4 und Jahreszahlen

 
  
    #2
12.11.16 13:29
http://www.4-traders.com/...uarter-FY2016-Financial-Results-23386243/

Gute Zahlen und Dividendenzahler, bleibt interessant.    

2458 Postings, 4149 Tage TamakoschyKurs nach Q1 17 Zahlen über 5 % im plus

 
  
    #3
10.01.17 16:55
Simulations Plus Reports First Quarter FY2017 Financial Results
Consolidated net earnings up 23.1% on 12% revenue increase

January 09, 2017
 

Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its first quarter of fiscal year 2017, the period ended November 30, 2016 (1QFY17).
1QFY17 highlights compared with 1QFY16:
Net revenues increased 12.0%, or $579,000, to a new first quarter record $5.42 million vs. $4.84 million
Gross profit increased 8.7% to $4.08 million from $3.76 million
SG&A was $1.86 million, an increase of $187,000 or 11.2%, from $1.68 million
SG&A as a percentage of revenues decreased slightly from 34.6% to 34.4%
Income before taxes increased $250,000 or 14.6%, to $1.97 million from $1.72 million
Net income increased $255,000 or 23.1%, to $1.36 million from $1.11 million
Diluted earnings per share increased 22% or $0.014, to $0.078 from $0.064 per share



https://www.irdirect.net/prviewer/release/id/2276824


 

2458 Postings, 4149 Tage TamakoschyQ2 17 es geht wieder abwärts

 
  
    #4
11.04.17 21:16
https://seekingalpha.com/pr/...econd-quarter-fy2017-financial-results

EPS of $0.07 misses by $-0.01 | Revenue of $ (- 100.0% Y/Y) misses by $-5.54M

Record second quarter as revenues grow 10.5%, 6MoFY17 net income up 13.6%
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its second quarter of fiscal year 2017, the period ended February 28, 2017 (2QFY17).  

2458 Postings, 4149 Tage TamakoschyFourth-Quarter-and-Fiscal-Year-2017

 
  
    #7
14.10.17 12:19

2458 Postings, 4149 Tage TamakoschyFY2017 and Fourth Quarter FY2017 Financial Results

 
  
    #8
15.11.17 17:13
Full Fiscal Year Pharmaceutical Software and Services Revenues Up 20.9%;
Earnings per share of $0.33, up 14.9% over prior year

http://www.4-traders.com/...uarter-FY2017-Financial-Results-25506597/  

2458 Postings, 4149 Tage TamakoschyQ1 18 wieder gut

 
  
    #9
11.01.18 18:31

2458 Postings, 4149 Tage Tamakoschyannual government license for its flagship QSP

 
  
    #11
10.05.18 08:37

2458 Postings, 4149 Tage TamakoschyQ4

 
  
    #17
14.11.19 07:29
https://www.marketscreener.com/...-FY2019-Financial-Results-29574276/

Full Year FY19 highlights compared with Full Year FY18:
Revenues were $34.0 million, up 14.5% over $29.7 million in FY18
Gross profit was up 15.1%, or $3.3 million, to $24.9 million, from $21.7 million in FY18
SG&A was $11.8 million, an increase of $2.2 million, or 23.1%, over $9.6 million
Total R&D expenditures were $4.3 million, an increase of $363,000, or 9.2% over $3.9 million
For FY19, $1.8 million was capitalized and $2.5 million was expensed
For FY18, $2.1 million was capitalized and $1.8 million was expensed
Income before taxes increased 4.1% to $10.6 million, an increase of $418,000 over $10.1 million
Net income decreased 3.9% to $8.6 million, a decrease of $351,000 from $8.9 million; FY18 included the one-time second-quarter tax benefit of $1.5 million
Diluted earnings per share decreased 5.0% to $0.48 from $0.50. In FY18, the major change in diluted earnings per share came from the $1.5 million tax adjustment that accounted for an $0.08 increase in diluted earnings per share
Cash was $11.4 million, an increase of $2.0 million, or 21.6%, from $9.4 million at the end of FY18.
4QFY19 highlights compared with 4QFY18:
Revenues increased 20.0% to $8.0 million, an increase of $1.3 million over $6.7 million
Gross profit was up 25.6% to $5.7 million, an increase of $1.2 million over $4.6 million
SG&A was $3.2 million, an increase of 42.6%, or $951,000, over $2.2 million
Total R&D expenditures were $1.0 million, an increase of $89,000, or 9.4%, over $951,000
For 4QFY19, $437,000 was capitalized and $603,000 was expensed
For 4QFY18, $514,000 was capitalized and $437,000 was expensed
Income before taxes increased 7.9% to $2.0 million, an increase of $146,000 over $1.8 million
Net income increased 53.9% to $2.1 million, an increase of $721,000 over $1.3 million
Earnings per fully diluted share increased $0.03 to $0.11 from $0.08  

2458 Postings, 4149 Tage TamakoschyQ1 20 wieder stark

 
  
    #18
10.01.20 20:07
https://www.marketscreener.com/...scal-1Q-Earnings-Snapshot-29814646/

https://www.marketscreener.com/...n-of-Operations-form-10-Q-29815181/

Simulations Plus: Fiscal 1Q Earnings Snapshot

LANCASTER, Calif. (AP) _ Simulations Plus Inc. (SLP) on Thursday reported fiscal first-quarter profit of $2.1 million.
The Lancaster, California-based company said it had net income of 11 cents per share.
The maker of software used in pharmaceutical research posted revenue of $9.4 million in the period.
Simulations Plus shares have risen 8.5% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $31.55, a rise of 55% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SLP at https://www.zacks.com/ap/SLP  

2458 Postings, 4149 Tage TamakoschyQ2 2020

 
  
    #19
1
13.04.20 17:39
https://www.marketscreener.com/...scal-2Q-Earnings-Snapshot-30393598/

Simulations Plus: Fiscal 2Q Earnings Snapshot
share with twitter share with LinkedIn share with facebook share via e-mail
0
04/09/2020 | 09:46pm BST
LANCASTER, Calif. (AP) _ Simulations Plus Inc. (SLP) on Thursday reported fiscal second-quarter profit of $2.2 million.

On a per-share basis, the Lancaster, California-based company said it had net income of 12 cents.

The maker of software used in pharmaceutical research posted revenue of $10.3 million in the period. Its adjusted revenue was $10.4 million.

Simulations Plus shares have increased 24% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $35.95, a rise of 80% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SLP at https://www.zacks.com/ap/SLP

Automated Insights, source Associated Press News

 

334 Postings, 609 Tage SkeelEinstieg Lohnenswert ?

 
  
    #20
22.06.20 09:25
Danke für die Posts  

2458 Postings, 4149 Tage TamakoschyEinstieg

 
  
    #21
22.06.20 20:47
Moinsen Skeel,

gute Aktien sind selten günstig. Ob man noch einsteigen sollte und wenn ja wann? Die Entscheidung kann Dir leider abnehmen. Ob noch eine Korrektur kommt? Bin hier aber schon lange investiert und bleibe es.  

2458 Postings, 4149 Tage TamakoschySteigt weiter nach Zahlen

 
  
    #22
10.07.20 16:49
https://www.marketscreener.com/...scal-3Q-Earnings-Snapshot-30901551/

Simulations Plus: Fiscal 3Q Earnings Snapshot
share with twitter share with LinkedIn share with facebook

07/09/2020 | 09:17pm BST
LANCASTER, Calif. (AP) _ Simulations Plus Inc. (SLP) on Thursday reported fiscal third-quarter profit of $2.9 million.

On a per-share basis, the Lancaster, California-based company said it had net income of 16 cents. Earnings, adjusted for costs related to mergers and acquisitions, were 20 cents per share.

The maker of software used in pharmaceutical research posted revenue of $12.3 million in the period.



 

2458 Postings, 4149 Tage TamakoschyZahlen Teil 2

 
  
    #23
11.07.20 07:40
FQ3: 07-09-20 Earnings Summary
Transcript
EPS of $0.2081 beats by $0.15 Revenue of $12.3M (23.76% Y/Y) beats by $1.09M
Third Quarter and 9MoFY20 Revenues Grow 24%
Board of Directors Announces Quarterly Dividend of $0.06 per Share
Company Files Shelf Registration Statement

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported financial results for its third quarter of fiscal year 2020 (3QFY20) and the first nine months of fiscal year 2020 (9moFY20), the period ended May 31, 2020.

3QFY20 highlights compared with 3QFY19:

Net revenues increased 23.8% to $12.3 million, an increase of $2.4 million over $9.9 million
Gross profit was up 26.5% to $9.6 million, an increase of $2.0 million over $7.6 million
SG&A was $5.0 million, an increase of 62.6% or $1.9 million over $3.1 million
SG&A as a percentage of revenues increased to 40.9% from 31.1%, inclusive of $1.1 million in one-time transaction costs related to the Lixoft acquisition
Total R&D expenditures were $1,359,000, an increase of $293,000, or 27.5% over $1,066,000

Weiter hier:
https://seekingalpha.com/pr/...third-quarter-fy2020-financial-results

 

4915 Postings, 1319 Tage KörnigUmsatzrückgang hört sich gar nicht

 
  
    #24
26.11.20 18:43
gut an  

2458 Postings, 4149 Tage TamakoschyQ2 - Results - Earnings Call Presentation

 
  
    #25
13.04.21 12:01

   Antwort einfügen - nach oben